New Avandia Study Finds Higher Risk Of Heart Problems And Death

Published: December 12, 2007, 7:44 am

Tags: nutrition, cardiovascular, diabetes

A new Canadian study on older patients who took diabetes medications known as thiazolidinediones (which include rosiglitazone or Avandia), concluded they ran a significantly higher risk of congestive heart failure, heart attack, and death compared with patients on other diabetes drugs.The researchers said their study provides further evidence that thiazolidinediones (TZDs) do more harm than good. GlaxoSmithKline, who market Avandia said the study was misleading and conflicted with more robust clinical studies.The study is published today, 12th December, in the early online issue of the Journal of the American Medical Association (JAMA) and is the work of Dr Lorraine L Lipscombe of the Institute for Clinical Evaluative Sciences, Toronto, Canada, and colleagues.The TZDs rosiglitazone (brand name Avandia, marketed by Glaxosmithkline) and pioglitazone (brand name Actos, marketed by Takeda), are oral medications taken by patients with type 2 diabetes to help control blood sugar (glycemic

[ Full article ]

Blog link

Rating: 0

Comments